USE OF CHIMERIC ANTI-CD20 ANTIBODY AS IN VITRO OR IN VIVO PURGING AGENT IN PATIENTS RECEIVING BMT OR PBSC TRANSPLANT
The use of anti-CD20 antibodies as in vivo purging agents for patients receiving bone marrow or peripheral blood stem cell transplant during treatment of B-cell-related diseases, e.g., B-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraftment and/or prevent disease relapse in such patients.
1 . A method for reducing the risk of relapse of a B-cell-related disease in a patient receiving a bone marrow or peripheral blood stem cell transplant comprising treating the transplant in vivo with an amount of an anti-CD20 antibody effective to reduce the number of disease-causing CD20 antigen-expressing cells in the transplant.
2 . The method of claim 1 , wherein the disease is a B-cell lymphoma or leukemia.
3 . The method of claim 1 , wherein the transplant is treated by administering rituximab to the patient within about one month after the patient receives the transplant.
4 . The method of claim 3 , wherein rituximab is administered to the patient at a dosage ranging from about 0.1 to about 20 mg/kg about one week after the patient receives the transplant.
5 . The method of claim 4 , wherein the patient has previously received treatment to eradicate disease-causing B-cells.
6 . The method of claim 5 , wherein the previously received treatment comprises whole body irradiation, rituximab immunotherapy, chemotherapy, cytokine therapy, radioimmunotherapy, or a combination thereof.
7 . The method of claim 2 , wherein the anti-CD20 antibody is a chimeric, humanized, or human antibody.
8 . A method for reducing the risk of relapse of a B-cell-related disease in a patient receiving a bone marrow or peripheral blood stem cell transplant, which patient has previously received treatment to eradicate disease-causing B-cells, comprising treating the transplant in vivo concurrent with or up to 100 days after transplantation with an amount of an antibody that binds human CD20 effective to reduce the number of disease-causing CD20 antigen expressing cells in the transplant.
9 . The method of claim 8 , wherein the disease is a B-cell lymphoma or leukemia.
10 . The method of claim 8 , wherein the transplant is treated by administering rituximab to the patient within about one month after the patient receives the transplant.
11 . The method of claim 10 , wherein rituximab is administered to the patient at a dosage ranging from about 0.1 to about 20 mg/kg about one week after the patient receives the transplant.
12 . The method of claim 8 , wherein the previously received treatment comprises whole body irradiation, rituximab immunotherapy, chemotherapy, cytokine therapy, radioimmunotherapy, or a combination thereof.
13 . The method of claim 9 , wherein the anti-CD20 antibody is a chimeric, humanized, or human antibody.
14 . The method of claim 12 , wherein the patient previously received radioimmunotherapy.
15 . The method of claim 8 , wherein the combined treatment protocol provides a synergistic effect when compared to either the transplant treatment alone or the anti-CD20 antibody treatment alone.